241 related articles for article (PubMed ID: 27379887)
1. Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
Härmark L; Raine J; Leufkens H; Edwards IR; Moretti U; Sarinic VM; Kant A
Drug Saf; 2016 Oct; 39(10):883-90. PubMed ID: 27379887
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
4. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
6. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
[TBL] [Abstract][Full Text] [Related]
7. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
Smith MY; Benattia I
Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
[TBL] [Abstract][Full Text] [Related]
8. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
10. Patient's reporting of adverse drug reactions: Which added value in 2023?
Bagheri H
Therapie; 2024; 79(2):155-159. PubMed ID: 38036329
[TBL] [Abstract][Full Text] [Related]
11. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
van Hunsel F; de Waal S; Härmark L
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
[TBL] [Abstract][Full Text] [Related]
12. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
[TBL] [Abstract][Full Text] [Related]
13. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
14. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
15. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
[TBL] [Abstract][Full Text] [Related]
16. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
Rehan HS; Chopra D; Holani SN; Mishra R
Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
[TBL] [Abstract][Full Text] [Related]
17. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
18. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
19. An Evaluation of Indian Consumers' Reporting of Suspected Adverse Drug Reactions with a Designated Reporting Form.
Rehan HS; Sah R; Gupta A; Nagar P
Curr Drug Saf; 2017; 12(1):51-56. PubMed ID: 27188794
[TBL] [Abstract][Full Text] [Related]
20. The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.
Sienkiewicz K; Burzyńska M; Rydlewska-Liszkowska I; Sienkiewicz J; Gaszyńska E
Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
